NCCN临床实践指南_系统性肥大细胞增多症(2019.V1)英文版
33页1、NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines Continue Version 1 2019 09 07 18 National Comprehensive Cancer Network Inc 2018 All rights reserved The NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN Systemic Mastocytosis Version 1 2019 September 7 2018 NCCN org NCCN Guidelines Index Table of Contents Discussion Version 1 2019 09 07 18 National Comprehensive Cancer Network Inc 2018 All rights reserved The NCCN G
2、uidelines and this illustration may not be reproduced in any form without the express written permission of NCCN NCCN Guidelines Version 1 2019 Panel Members Systemic Mastocytosis NCCN Mary Anne Bergman Hema Sundar PhD NCCN Guidelines Panel Disclosures Continue Aaron T Gerds MD MS Chair Case Comprehensive Cancer Center University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Jason Gotlib MD MS Vice Chair Stanford Cancer Institute Prithviraj Bose MD The University
3、of Texas MD Anderson Cancer Center Mariana C Castells MD PhD Adjunct Dana Farber Cancer Institute Michael W Deininger MD PhD Huntsman Cancer Institute at the University of Utah Ivana Gojo MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Krishna Gundabolu MBBS Fred see 2017 WHO Diagnostic Criteria for Cutaneous and Systemic Mastocytosis SM B and see 2017 Diagnostic Criteria for the Variants of Systemic Mastocytosis SM C bPatients should be counseled about the signs symptoms and p
4、otential triggers of mast cell activation See SM H Multidisciplinary collaboration with sub specialists eg anesthesia for procedures surgery high risk OB for pregnancy is recommended cSerum tryptase level may be 20 ng mL or only transiently elevated dSee WHO Criteria for B Findings and C Findings in Patients with Systemic Mastocytosis SM D and IWG MRT ECNM Criteria for Eligible Organ Damage to Assess Clinical Improvement CI and Treatment Response SM E B and C findings are used for the diagnosis
5、of the WHO subtype of SM SM C and SM D and IWG MRT ECNM criteria are used to establish eligible organ damage findings for clinical trial enrollment and to adjudicate response to therapy SM E eMast cell markers by flow cytometry immunophenotyping include CD117 CD25 and CD2 Immunohistochemistry markers include CD117 CD25 and tryptase For both techniques CD30 is optional Also see SM 2 fSpecific criteria have been established for primary and secondary MCAS Akin C Mast cell activation syndromes J All
《NCCN临床实践指南_系统性肥大细胞增多症(2019.V1)英文版》由会员沧海****3分享,可在线阅读,更多相关《NCCN临床实践指南_系统性肥大细胞增多症(2019.V1)英文版》请在金锄头文库上搜索。
洁厕灵企业技术标准范例
发电企业热工设备检修规程
发电企业热控日常点检标准
发电企业汽机(含燃机)技术监督细则
发电企业电气设备保护及安全自动装置投退和定值变更管理标准
继电保护定值变更通知单
继电保护及安全自动装置投退审批表
电气保护定值更改申请单
化工企业粉尘涉爆企业整体安全风险等级评估方法
化工企业安全检查管理规程
电气安全管理规程范例
农业企业绿色食品大棚生菜生产操作规程
农业企业绿色食品桃园管理规程
农业企业绿色食品早春蕹菜生产操作规程
农业企业绿色食品大棚蚕豆促早栽培生产技术操作规程
农业企业绿色食品荠菜种植规程
农业企业绿色食品青椒种植规程
农业企业绿色食品筒篙种植规程
农业企业绿色食品油麦菜种植规程
农业企业绿色食品木耳菜种植规程
2023-05-11 11页
2022-09-05 10页
2022-08-18 10页
2022-08-18 6页
2022-08-18 7页
2022-08-18 3页
2022-08-18 5页
2022-08-18 9页
2022-08-18 7页
2022-08-18 4页